Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
Open Access
- 29 April 2014
- journal article
- review article
- Published by Hindawi Limited in BioMed Research International
- Vol. 2014, 1-9
Abstract
Liver metastasis in solid tumors, including colorectal cancer, is the most frequent and lethal complication. The development of systemic therapy has led to prolonged survival. However, in selected patients with a finite number of discrete lesions in liver, defined as oligometastatic state, additional local therapies such as surgical resection, radiofrequency ablation, cryotherapy, and radiotherapy can lead to permanent local disease control and improve survival. Among these, an advance in radiation therapy made it possible to deliver high dose radiation to the tumor more accurately, without impairing the liver function. In recent years, the introduction of stereotactic ablative radiotherapy (SABR) has offered even more intensive tumor dose escalation in a few fractions with reduced dose to the adjacent normal liver. Many studies have shown that SABR for oligometastases is effective and safe, with local control rates widely ranging from 50% to 100% at one or two years. And actuarial survival at one and two years has been reported ranging from 72% to 94% and from 30% to 62%, respectively, without severe toxicities. In this paper, we described the definition and technical aspects of SABR, clinical outcomes including efficacy and toxicity, and related parameters after SABR in liver oligometastases from colorectal cancer.Keywords
This publication has 47 references indexed in Scilit:
- Single-dose radiosurgical treatment for hepatic metastases - therapeutic outcome of 138 treated lesions from a single institutionRadiation Oncology, 2013
- Stereotactic body radiotherapy for oligometastasesThe Lancet Oncology, 2013
- Stereotactic Body Radiation Therapy for Patients with Heavily Pretreated Liver Metastases and Liver TumorsFrontiers in Oncology, 2012
- Image-Guided Robotic Stereotactic Body Radiation Therapy for Liver Metastases: Is There a Dose Response Relationship?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Stereotactic body radiotherapy for colorectal liver metastasesCancer, 2011
- Phase I Study of Individualized Stereotactic Body Radiotherapy of Liver MetastasesJournal of Clinical Oncology, 2009
- Stereotactic radiotherapy of primary liver cancer and hepatic metastasesActa Oncologica, 2006
- Phase II study on stereotactic body radiotherapy of colorectal metastasesActa Oncologica, 2006
- Extending the Frontiers of Surgical Therapy for Hepatic Colorectal Metastases: Is There a Limit?Journal of Clinical Oncology, 2005
- Systemic Therapy for Colorectal CancerNew England Journal of Medicine, 2005